공시 • Mar 17
Psomagen, Inc., Annual General Meeting, Mar 31, 2026 Psomagen, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea Board Change • Jul 15
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mi-Rye Kim was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Mar 18
Psomagen, Inc., Annual General Meeting, Mar 31, 2025 Psomagen, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea Buy Or Sell Opportunity • Aug 05
Now 31% undervalued after recent price drop Over the last 90 days, the stock has fallen 17% to ₩4,020. The fair value is estimated to be ₩5,796, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last year. Earnings per share has declined by 1,037%. Buy Or Sell Opportunity • Jul 01
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 24% to ₩3,940. The fair value is estimated to be ₩5,109, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last year. Earnings per share has declined by 1,037%. Buy Or Sell Opportunity • Jun 19
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 34% to ₩3,995. The fair value is estimated to be ₩5,093, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last year. Earnings per share has declined by 1,037%. New Risk • Mar 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (₩103.9b market cap, or US$77.6m). New Risk • Jan 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩100.0b market cap, or US$74.3m). 공시 • Sep 13
Psomagen Announces the Launch of Spatial Biology Services for 10X Genomics Xenium™? Multiomics CRO Psomagen announced the launch of Spatial Biology services for 10X Genomics Xenium™?. This platform is reshaping spatial biology, enabling researchers worldwide to analyze the interplay of genes and proteins within their native tissue context. This marks a pivotal moment in the scientific community's access to spatial genomics. Key Features of Psomagen's Xenium Service: Precision: Xenium's spatial profiling provides unprecedented precision and sensitivity. Pinpoint gene expression patterns within single cells in context, enabling a deeper understanding of cellular heterogeneity and function. Multiomics Approach: Psomagen integrates various omics platforms, including genomics, transcriptomics, and proteomics. Researchers can analyze the molecular landscape of tissues and the interplay between molecular components. Quality: Psomagen's stringent quality controls are built into every project. Psomagen is a 10X Genomics and Olink Certified Service Provider with CAP and CLIA accreditations. Expertise: Psomagen's experienced scientists and bioinformaticians ensure researchers receive comprehensive support throughout their projects. New Risk • Jul 01
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩131.7b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩131.7b market cap, or US$100.0m). Reported Earnings • Nov 20
Third quarter 2022 earnings released: EPS: ₩51.00 (vs ₩90.00 loss in 3Q 2021) Third quarter 2022 results: EPS: ₩51.00 (up from ₩90.00 loss in 3Q 2021). Revenue: ₩12.4b (up 87% from 3Q 2021). Net income: ₩1.03b (up ₩2.67b from 3Q 2021). Profit margin: 8.3% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. 공시 • Feb 24
Psomagen, Inc. Expands Precision Genomics Capabilities with 10x Genomics’ Single Cell Sequencing Technologies Psomagen, Inc. expands its next-generation sequencing capabilities to include end-to-end single cell sequencing (SCS) services. These services, which include gene expression and single cell immune profiling, are powered by the Chromium platform and Next GEM-based technology from 10x Genomics, a life science technology company building products to interrogate, understand, and master biology. SCS is being used to help scientists better understand the mechanisms of infection and immune response at the level of an individual cell. That knowledge is important because it helps learn how to better prevent and treat diseases like COVID-19, cancer, Alzheimer’s, and more. Psomagen’s SCS team is building on the company’s long-standing genomics expertise, handling the entire study workflow for its clients — from sample clean up and quality control to library preparation, sequencing, and analysis of complex cell populations. In less than three weeks, Psomagen’s clients have results and the detailed molecular insights they need to answer even the most complicated research questions. Is New 90 Day High Low • Feb 20
New 90-day low: ₩12,000 The company is down 47% from its price of ₩22,500 on 20 November 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. Is New 90 Day High Low • Feb 04
New 90-day low: ₩12,450 The company is down 14% from its price of ₩14,450 on 06 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. Is New 90 Day High Low • Nov 13
New 90-day high: ₩18,100 The company is up 10.0% from its price of ₩16,450 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Oct 15
New 90-day low: ₩13,300 The company is down 33% from its price of ₩20,000 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period. 
